Abstract
Transition metal complexes with terpyridine ligands have attracted a widespread interest with respect to biomedical applications: [(tpy)PtCl]Cl and [(tpy)RuCl3] are potent anti-tumor agents with activities comparable to those of cisplatin and carboplatin. The RuII complexes feature a high potential as reactive probes for DNA oxidation; whereas, luminescent IrIII, PtII or EuIII complexes have been utilized in biolabeling applications. Besides complexes based on heavy second or third row transition metal ions, remarkable results have been obtained with respect to the development of new types of metallodrugs, based on the naturally more abundant and intrinsically less toxic first row transition metal ions (e.g. FeII, CuI/II, ZnII). The perspective of these complexes in particular with respect to future biomedical applications in chemotherapy and cleavage of nucleic acids is evaluated in this review.
Keywords: Cytotoxicity, DNA cleavage, metallodrugs, self-assembly, supramolecular chemistry, terpyridine complexes, Transition metal complexes, DNA oxidation, nucleic acids, chemotherapy, carboplatin, superoxide dimutase, stereospecific transformations, potential metallodrugs
Current Topics in Medicinal Chemistry
Title: Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Volume: 12 Issue: 3
Author(s): Andreas Winter, Michael Gottschaldt, George R. Newkome and Ulrich S. Schubert
Affiliation:
Keywords: Cytotoxicity, DNA cleavage, metallodrugs, self-assembly, supramolecular chemistry, terpyridine complexes, Transition metal complexes, DNA oxidation, nucleic acids, chemotherapy, carboplatin, superoxide dimutase, stereospecific transformations, potential metallodrugs
Abstract: Transition metal complexes with terpyridine ligands have attracted a widespread interest with respect to biomedical applications: [(tpy)PtCl]Cl and [(tpy)RuCl3] are potent anti-tumor agents with activities comparable to those of cisplatin and carboplatin. The RuII complexes feature a high potential as reactive probes for DNA oxidation; whereas, luminescent IrIII, PtII or EuIII complexes have been utilized in biolabeling applications. Besides complexes based on heavy second or third row transition metal ions, remarkable results have been obtained with respect to the development of new types of metallodrugs, based on the naturally more abundant and intrinsically less toxic first row transition metal ions (e.g. FeII, CuI/II, ZnII). The perspective of these complexes in particular with respect to future biomedical applications in chemotherapy and cleavage of nucleic acids is evaluated in this review.
Export Options
About this article
Cite this article as:
Winter Andreas, Gottschaldt Michael, R. Newkome George and S. Schubert Ulrich, Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules, Current Topics in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/156802612799078919
DOI https://dx.doi.org/10.2174/156802612799078919 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Apoptotic Signaling Pathways as a Target for the Treatment of Liver Diseases
Mini-Reviews in Medicinal Chemistry Modifications of Isoalantolactone Leading to Effective Anti-bacterial and Anti-viral Compounds
Letters in Drug Design & Discovery Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme
Current Pharmaceutical Design Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Current Cancer Drug Targets Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Drug-Targeting Strategies for Prostate Cancer
Current Pharmaceutical Design Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Design, Development and Characterization of Topical Microemulsions of 5-Fluorouracil for the Treatment of Non Melanoma Skin Cancer and its Precursor Lesions.
Anti-Cancer Agents in Medicinal Chemistry Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Study of Cancer Cell Lines with Fourier Transform Infrared (FTIR)/ Vibrational Absorption (VA) Spectroscopy
Current Physical Chemistry